About Ribocure

About us

Ribocure Pharmaceuticals AB is a clinical stage biotech company with a business focus on the development of cutting-edge RNA therapeutics.

Ribocure’s primary focus lies in addressing the significant medical gaps in rare diseases involved in the fields of cardiovascular, renal, and oncology. The company is dedicated to the discovery and development of groundbreaking drug assets utilizing advanced oligonucleotide technologies.

Operating as a subsidiary of Ribo Life Science Co., Ltd., Ribocure leverages the advantages of a vertically integrated oligonucleotide research platform and excels in translational and clinical operations. Our comprehensive technological platforms encompass the entire process, from sequence design, screening, and optimization to delivery technologies and large-scale commercial CMC capacity. 

In 2022, we successfully progressed three projects to the clinical stage, achieving an impressive average time frame of 20-24 months from concept to implementation.

the heart

Mission and Vision


To provide patients with effective, safe and affordable RNA therapeutics to enhance their quality of life by decreasing or eliminating their disease burden.


To become a world-leading RNA therapeutics company to help patients in need.

Internal drivers

Global Project

Portfolio Build

Global Business Development

Global Science and Talent

Core Values

Oligonucleotide therapeutics

Science driven









patient centered


ribocure clinic

On the entire fifth floor of the GoCo Clinic building, Ribocure has established a unique “from bench-to-bed” set-up with an R&D department, a Ph2 clinical trial unit, ribocure clinic and an in vitro human cell lab.

The Ribocure Clinic is dedicated and specialized for high quality proof of principle/concept and phase 2 trials within our clinical expertise areas including a functional imaging core lab capacity.

Contact us for collaboration opportunities and projects ideas!

Ribocure will be expanding heavily in Sweden and looking for new talents to join, and academic associations as well as small and large enterprise partners to collaborate with, with the joint goal of developing highly differentiated and innovative oligonucleotide therapeutics to help patients in need. 

Privacy Policy (Integritetspolicy)
Your privacy is important to us. Ribocure Pharmaceuticals AB respects your privacy regarding all data we may collect from you on our website, www.ribocure.com.
We collect data/information to make contact and establish and maintain a relationship. We collect this information in a fair and legal way with your awareness and consent, as stipulated by GDPR (General Data Protection Regulation). We also let you know why we collect it and how it will be used.
The data that is stored are the fields that each submission form contains. We save the data for as long as is necessary with regard to the purposes of the processing. We always base the collection of personal data on consent.
You have the right to request information about what personal data we have stored about you. To do this, contact the Data Protection Officer (DPO). You also have the right to request correction or deletion of your personal data at any time.
Your continued use of our website will be deemed as acceptance of our privacy and personal information practices. If you have any questions about how we handle user data and personal information, please contact us.
Contact information to the Data Protection Officer (DPO):
Data Protection Officer
Ribocure Pharmaceuticals AB
Vetenskapens gränd 11
431 53 Mölndal
E-mail: dpo@ribocure.com